

28 NOV 2005

TMH:dv 11/20/05 4810-70826-01 82873-5

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re application of:** Gagnon et al.**Application No.** 10/528,542**Filed:** March 21, 2005**Confirmation No.** 3811**For:** GD2 LIGANDS**Examiner:** \_\_\_\_\_**Art Unit:** \_\_\_\_\_**Attorney Reference No.** 4810-70826-01**CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP MISSING PARTS, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent  
for Applicant(s)

Tanya M. Harding, Ph.D.

Date Mailed November 21, 2005

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

MAIL STOP MISSING PARTS  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are six English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. It is believed that no fee is due to file this IDS. If the Commissioner determines that a fee is due, Deposit Account authority is provided on the accompanying transmittal letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600  
121 S.W. Salmon Street  
Portland, Oregon 97204  
Telephone: (503) 595-5300  
Facsimile: (503) 595-5301

By

Tanya M. Harding, Ph.D.  
Registration No. 42,630

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/

<b>INFORMATION DISCLOSURE CITATION</b> Form PTO-1449 (Modified) <i>(Use several sheets if necessary)</i>	<b>ATTY. DOCKET NO.</b> 4810-70826-01	<b>SERIAL NO.</b> 10/528,542
	<b>APPLICANT</b> GAGNON, Martin et al.	
	<b>FILING DATE</b> 21 March 2005	<b>GROUP</b>

### U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A1					

### FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
B1					

### OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

/MA/	C1	Cheung, N.V. et al., <i>Cancer Research</i> 45, pp. 2642-2649 (June 1985)
	C2	Eisenberg, D. et al., <i>J. Mol. Biol.</i> 179, pp. 125-142 (1984)
	C3	Gagnon, Martin et al., <i>Expert Opinion</i> (2002)
	C4	Probstmeier et al., <i>Eur. J. Neuroscience</i> , Vol. 11, pp. 2474-2488 (1999)
	C5	Saragovi, H. Uri et al., <i>Nature Biotechnology</i> , Vol. 10, pp. 773-778 (July 1992)
/MA/	C6	Sorkin, L.S., <i>Pain Medicine</i> , Vol. 1, pp. 296-302 (2000)

<b>EXAMINER</b> /Maury Audet/	<b>DATE CONSIDERED</b> 04/29/2008
<b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MA/